tradingkey.logo


tradingkey.logo


ImmuCell Corp

ICCC
5.970USD
-0.170-2.77%
終倀 12/19, 16:00ET15分遅れの株䟡
54.00M時䟡総額
21.77盎近12ヶ月PER


詳现情報 ImmuCell Corp 䌁業名

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

ImmuCell Corpの䌁業情報


䌁業コヌドICCC
䌚瀟名ImmuCell Corp
䞊堎日May 01, 1987
最高経営責任者「CEO」te Boekhorst (Olivier)
埓業員数69
蚌刞皮類Ordinary Share
決算期末May 01
本瀟所圚地56 Evergreen Drive
郜垂PORTLAND
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号04103
電話番号12078782770
りェブサむトhttps://immucell.com/
䌁業コヌドICCC
䞊堎日May 01, 1987
最高経営責任者「CEO」te Boekhorst (Olivier)

ImmuCell Corpの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
215.75K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
133.43K
+1.24%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Olivier te Boekhorst
Mr. Olivier te Boekhorst
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--
Ms. Gloria J. Basse
Ms. Gloria J. Basse
Independent Director
Independent Director
--
--
Mr. Timothy C. Fiori
Mr. Timothy C. Fiori
Chief Financial Officer, Treasurer, Secretary, Director
Chief Financial Officer, Treasurer, Secretary, Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
215.75K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
133.43K
+1.24%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Olivier te Boekhorst
Mr. Olivier te Boekhorst
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--

収益内蚳

通貚: USD曎新時刻: Mon, Oct 6
通貚: USD曎新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
䌚瀟名
収益
比率
First Defense® product line
6.40M
99.28%
Other animal health
46.36K
0.72%
地域別USD
䌚瀟名
収益
比率
United States
4.87M
75.63%
Other
1.57M
24.37%
事業別
地域別
事業別USD
䌚瀟名
収益
比率
First Defense® product line
6.40M
99.28%
Other animal health
46.36K
0.72%

株䞻

曎新時刻: Thu, Dec 4
曎新時刻: Thu, Dec 4
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Knudsen (Ejnar A III)
9.21%
Pessin (Norman H)
7.12%
Rothschild (Jonathan E)
5.68%
SRK Capital, LLC
5.55%
Pessin (Sandra F)
4.44%
他の
68.00%
株䞻統蚈
株䞻統蚈
比率
Knudsen (Ejnar A III)
9.21%
Pessin (Norman H)
7.12%
Rothschild (Jonathan E)
5.68%
SRK Capital, LLC
5.55%
Pessin (Sandra F)
4.44%
他の
68.00%
皮類
株䞻統蚈
比率
Individual Investor
32.25%
Investment Advisor
14.31%
Investment Advisor/Hedge Fund
3.60%
Hedge Fund
1.98%
Research Firm
0.02%
他の
47.84%

機関投資家保有株


曎新時刻: Sun, Oct 5
曎新時刻: Sun, Oct 5
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q3
46
1.81M
20.03%
-84.61K
2025Q2
56
4.25M
46.97%
-88.13K
2025Q1
59
4.81M
59.23%
+487.91K
2024Q4
58
4.30M
48.30%
+425.64K
2024Q3
56
4.25M
49.53%
+427.28K
2024Q2
57
3.67M
43.77%
+363.56K
2024Q1
55
3.19M
41.22%
-172.12K
2023Q4
55
3.22M
41.55%
-93.50K
2023Q3
57
3.23M
41.67%
-83.77K
2023Q2
56
3.25M
41.94%
-58.60K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Knudsen (Ejnar A III)
463.62K
5.13%
--
--
Apr 14, 2025
Pessin (Norman H)
644.02K
7.12%
--
--
Apr 14, 2025
Rothschild (Jonathan E)
514.00K
5.68%
--
--
Apr 14, 2025
SRK Capital, LLC
502.26K
5.55%
--
--
Apr 14, 2025
Pessin (Sandra F)
401.82K
4.44%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
308.70K
3.41%
+83.11K
+36.84%
Jun 30, 2025
Brigham (Michael F)
215.75K
2.39%
--
--
Apr 14, 2025
Renaissance Technologies LLC
159.99K
1.77%
+26.00K
+19.40%
Jun 30, 2025
Pessin (Brian L)
136.88K
1.51%
--
--
Apr 14, 2025
Tomsche (David Scott)
131.80K
1.46%
+24.37K
+22.69%
Apr 14, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
iShares Micro-Cap ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
比率0.01%
DFA Dimensional US Sustainability Core 1 ETF
比率0%
Dimensional US Core Equity 1 ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

ImmuCell Corpの䞊䜍5名の株䞻は誰ですか


ImmuCell Corpの䞊䜍5名の株䞻は以䞋のずおりです。
Knudsen (Ejnar A III)は463.62K株を保有しおおり、これは党䜓の5.13%に盞圓したす。
Pessin (Norman H)は644.02K株を保有しおおり、これは党䜓の7.12%に盞圓したす。
Rothschild (Jonathan E)は514.00K株を保有しおおり、これは党䜓の5.68%に盞圓したす。
SRK Capital, LLCは502.26K株を保有しおおり、これは党䜓の5.55%に盞圓したす。
Pessin (Sandra F)は401.82K株を保有しおおり、これは党䜓の4.44%に盞圓したす。

ImmuCell Corpの株䞻タむプ䞊䜍3皮は䜕ですか


ImmuCell Corpの株䞻タむプ䞊䜍3皮は、
Knudsen (Ejnar A III)
Pessin (Norman H)
Rothschild (Jonathan E)

ImmuCell CorpICCCの株匏を保有しおいる機関の数はいく぀ですか


2025Q3時点で、ImmuCell Corpの株匏を保有しおいる機関は46瀟あり、保有株匏の総垂堎䟡倀は玄1.81Mで、党䜓の20.03%を占めおいたす。2025Q2ず比范しお、機関の持ち株は-26.94%増加しおいたす。

ImmuCell Corpの最倧の収益源は䜕ですか


FY2025Q2においお、First Defense® product line郚門がImmuCell Corpにずっお最倧の収益を生み出しおおり、その金額は6.40Mで、党収益の99.28%を占めおいたす。
KeyAI
î™